肝細胞腫瘤標記 PIVKA-II
PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II): Hepatocellular Carcinoma (HCC) Tumor Marker
*PIVKA-II, also known as abnormal prothrombin, is a highly specific tumor marker for hepatocellular carcinoma (HCC). It is produced as an abnormal protein due to the impaired synthesis of prothrombin in cases of vitamin K deficiency or liver cancer.
*Normal Range: < 40 mAU/mL (values may vary slightly depending on the laboratory)
*Causes of Elevated PIVKA-II
-Hepatocellular Carcinoma (HCC):
PIVKA-II is often significantly elevated in hepatocellular carcinoma patients, especially in advanced stages or when there is portal vein invasion, where the increase is more pronounced.
-Benign Liver Diseases:
In patients with chronic hepatitis or liver cirrhosis, PIVKA-II may be mildly elevated, but the elevation is not as significant as in HCC patients.
-Vitamin K Deficiency:
Prolonged vitamin K deficiency or the use of vitamin K antagonists (such as certain anticoagulant drugs) can lead to elevated PIVKA-II levels.
*Uses of PIVKA-II
-Aiding in the Diagnosis of Hepatocellular Carcinoma:
When used in conjunction with AFP (Alpha-Fetoprotein), PIVKA-II can improve the detection rate and diagnostic accuracy for hepatocellular carcinoma, especially in patients where AFP is negative.
-Monitoring Treatment Effectiveness:
Changes in PIVKA-II levels can be used to evaluate the effectiveness of treatment for liver cancer (e.g., surgery, interventional therapy, or targeted drug therapy). If treatment is effective, PIVKA-II levels typically decrease.
-Detecting Cancer Recurrence:
PIVKA-II is useful for monitoring recurrence of liver cancer after treatment, particularly in post-operative follow-ups.
*Health Recommendations
-Screening for High-Risk Groups:
Regular PIVKA-II testing is recommended for individuals with chronic hepatitis or liver cirrhosis, as it helps in the early detection of hepatocellular carcinoma.
-Further Investigation:
If PIVKA-II levels are significantly elevated, additional imaging tests (e.g., liver ultrasound, CT scan, MRI) and other tumor markers (such as AFP) should be used for comprehensive diagnosis.
-Monitoring Treatment and Recurrence:
Once hepatocellular carcinoma is diagnosed, PIVKA-II can be used to monitor treatment effectiveness and for early detection of recurrence.
*Conclusion
PIVKA-II is a crucial tumor marker for hepatocellular carcinoma (HCC), especially in patients who are AFP-negative. It plays a key role in diagnosis, treatment monitoring, and recurrence detection of liver cancer. However, it should be used in combination with other diagnostic methods for a comprehensive assessment.
*PIVKA-II, also known as abnormal prothrombin, is a highly specific tumor marker for hepatocellular carcinoma (HCC). It is produced as an abnormal protein due to the impaired synthesis of prothrombin in cases of vitamin K deficiency or liver cancer.
*Normal Range: < 40 mAU/mL (values may vary slightly depending on the laboratory)
*Causes of Elevated PIVKA-II
-Hepatocellular Carcinoma (HCC):
PIVKA-II is often significantly elevated in hepatocellular carcinoma patients, especially in advanced stages or when there is portal vein invasion, where the increase is more pronounced.
-Benign Liver Diseases:
In patients with chronic hepatitis or liver cirrhosis, PIVKA-II may be mildly elevated, but the elevation is not as significant as in HCC patients.
-Vitamin K Deficiency:
Prolonged vitamin K deficiency or the use of vitamin K antagonists (such as certain anticoagulant drugs) can lead to elevated PIVKA-II levels.
*Uses of PIVKA-II
-Aiding in the Diagnosis of Hepatocellular Carcinoma:
When used in conjunction with AFP (Alpha-Fetoprotein), PIVKA-II can improve the detection rate and diagnostic accuracy for hepatocellular carcinoma, especially in patients where AFP is negative.
-Monitoring Treatment Effectiveness:
Changes in PIVKA-II levels can be used to evaluate the effectiveness of treatment for liver cancer (e.g., surgery, interventional therapy, or targeted drug therapy). If treatment is effective, PIVKA-II levels typically decrease.
-Detecting Cancer Recurrence:
PIVKA-II is useful for monitoring recurrence of liver cancer after treatment, particularly in post-operative follow-ups.
*Health Recommendations
-Screening for High-Risk Groups:
Regular PIVKA-II testing is recommended for individuals with chronic hepatitis or liver cirrhosis, as it helps in the early detection of hepatocellular carcinoma.
-Further Investigation:
If PIVKA-II levels are significantly elevated, additional imaging tests (e.g., liver ultrasound, CT scan, MRI) and other tumor markers (such as AFP) should be used for comprehensive diagnosis.
-Monitoring Treatment and Recurrence:
Once hepatocellular carcinoma is diagnosed, PIVKA-II can be used to monitor treatment effectiveness and for early detection of recurrence.
*Conclusion
PIVKA-II is a crucial tumor marker for hepatocellular carcinoma (HCC), especially in patients who are AFP-negative. It plays a key role in diagnosis, treatment monitoring, and recurrence detection of liver cancer. However, it should be used in combination with other diagnostic methods for a comprehensive assessment.